EMA Is Exploring How Real-World Data Can Benefit Europe’s OTC Market, Says Agency Head Rasi

The European Medicines Agency is right now looking into how real-world data and evidence can be used to improve regulatory systems and extend access to OTC medicines within the European Union, the agency's executive director Guido Rasi told the recent AESGP Regulatory Conference in Amsterdam.

Real world data
Real-world data can be used to expand access to OTCs • Source: Shutterstock

“Real-world data” (RWD) and “real-world evidence” (RWE) are fast becoming buzzwords in the global consumer healthcare industry, often mentioned with excitement within discussions about the future of the global OTC market.

For firms, RWD generated through smartphone apps and wearables offers a cost-efficient way to supplement the expensive clinical evidence needed...

More from Regulation

More from Policy & Regulation

Pharma Deutschland Seeks To Enter Urban Wastewater Legal Dispute

 
• By 

The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By 

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.